Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals
EPIC: XEN
Latest Price: 6.00  (0,00%)
52-week High: 11.88
52-week Low: 5.88
Market Cap: 24.47M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Xenetic Biosciences
www.lipoxen.co.uk

Xenetic Biosciences (formally Lipoxen) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs. 

The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic Biosciences 's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.

Full Xenetic Biosciences profile here
Pdf

Xenetic Biosciences raises £12.2 million via share subscription

29th Nov 2011, 10:48 am by Jon Mainwaring

 

Biopharmaceutical firm Xenetic Biosciences (LON:XEN) reported this morning that it had completed the subscription agreement it arranged in August to raise £12.2 million.

Xenetic deal’s with SynBio – a Russian drug development company – was to raise £12.2 million in exchange for 110.8 million shares in Xenetic at 11 pence each (which represents a premium of 69.2 per cent to Xenetic’s closing price yesterday).

The firm also revealed in August that it would be buying German firm SymbioTec – a developer of technology that uses highly-alkaline proteins to treat a broad spectrum of cancers. Today, it said that it expects the completion of this acquisition will occur no later than December 15.

“The company now has the capital to accelerate its drug development pipeline and, in our view, significantly enhance shareholder value,” said M. Scott Maguire, Xenetic’s chief executive officer. “Our primary focus will be on the positive human clinical data that is being generated by our partnerships in Russia and India, thereby providing comfort on the drug candidates' potential for success.”

Maguire added that the firm’s de-risked approach to biotech development “is exemplified through the 12 novel drug candidates under the Russian and Indian human proof of concept initiatives” and that this, combined with the potentially large number of additional new candidates that can be developed using the firm’s platform technologies, “is expected to yield significant shareholder value going forward”.


 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.